Edgewise Therapeutics, Inc.

NASDAQ:EWTX

35.51 (USD) • At close October 17, 2024
Bedrijfsnaam Edgewise Therapeutics, Inc.
Symbool EWTX
Munteenheid USD
Prijs 35.51
Beurswaarde 3,329,854,373
Dividendpercentage 0%
52-weken bereik 5.12 - 36.66
Industrie Biotechnology
Sector Healthcare
CEO Dr. Kevin Koch Ph.D.
Website https://www.edgewisetx.com

An error occurred while fetching data.

Over Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops

Vergelijkbare Aandelen

LianBio logo

LianBio

LIAN

0.319 USD

Zynex, Inc. logo

Zynex, Inc.

ZYXI

7.95 USD

Phathom Pharmaceuticals, Inc. logo

Phathom Pharmaceuticals, Inc.

PHAT

16.24 USD

Radius Health, Inc. logo

Radius Health, Inc.

RDUS

18.5 USD

Eiger BioPharmaceuticals, Inc. logo

Eiger BioPharmaceuticals, Inc.

EIGR

1.725 USD

Aadi Bioscience, Inc. logo

Aadi Bioscience, Inc.

AADI

2.15 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)